Measurement of HE4 six months after first-line treatment as optimal time in identifying patients at high risk of progression advanced ovarian cancer.

Autor: Kotowicz BU; Independent laboratory of Tumor Biomarkers and Cytokines, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland. beata.kotowicz@pib-nio.pl., Fuksiewicz M; Independent laboratory of Tumor Biomarkers and Cytokines, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland., Bidzinski M; Department of Gynecologic Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland., Berezowska A; Independent laboratory of Tumor Biomarkers and Cytokines, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland., Sobiczewski P; Department of Gynecologic Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland., Kowalska MM; Independent laboratory of Tumor Biomarkers and Cytokines, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.

Publikováno v: Ginekologia polska [Ginekol Pol] 2022; Vol. 93 (11), pp. 910-915.